News

Genoskin appoints Eric Merle as first chief commercial officer   Salem, MA. – January 4, 2019 – Genoskin, an innovative provider of ex vivo clinical testing skin models and solutions, announced today the addition of Eric Merle as the company’s first chief commercial officer. The new position will see him take responsibility for all regions in which Genoskin operates. Eric has

Read more

Thank you so much for making this past year outstanding! We look forward to further our partnerships and helping you develop more relevant data for 2019! Best wishes of success. The Genoskin team. To keep up-to-date with Genoskin’s latest news, follow us on Twitter and LinkedIn. You can also contact us to learn more about our activities and services.

NativeSkin kit now available for lab delivery on Mondays! We have great news! We have been working hard to optimize our technology and processes this year. We are now able to offer a solution to those seeking to work on our NativeSkin kits throughout the work week. If you order NativeSkin kit, we will prepare and ship them in time for you to receive them on Mondays. Our proprietaryRead more

Genoskin, Inc. offre un poste de manager de laboratoire et chef de projet basé à Salem dans la région de Boston (MA), sous la forme d’un Volontariat International en Entreprise (VIE). Venez nous rejoindre ! Rémunération : Compensation nette d’environ 36 K EUR / an + compensation frais hébergement Date de début : Dès que possible Contrat : CDD de 2

Read more

Genoskin signs distribution agreement with Japan's Fujifilm Wako Pure Chemical The Genoskin team is excited to announce that we've signed an agreement with the Japanese Fujifilm Wako Pure Chemical Corporation to distribute Genoskin's ex vivo human skin models to customers in Japan. This agreement will enable Genoskin to respond to the specific needs of exisiting and potential customers in Japan and to increase itsRead more

New study model for injectable anti-psoriasis drugs A hi-tech psoriasis skin model to study drug efficacy To evaluate the efficacy of injectable anti-psoriasis drugs, the Genoskin team has designed a new test model that combines the InflammaSkin® and HypoSkin® technologies. Below you’ll find a proof-of-concept case study that illustrates the relevance of the new Hypo-InflammaSkin® model during efficacy studies of injectableRead more